Acute Myocardial Infarction (AMI)
Conditions
Brief summary
This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.
Interventions
None listed
Sponsors
The Affiliated Hospital of Hangzhou Normal University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Age ≥ 60 years old and meet the above comprehensive aging assessment criteria (i.e., combined with at least one clinical phenotype of aging and abnormal blood aging markers on the basis of advanced age); 2. Acute myocardial infarction occurs for ≥ 3 months; 3. Meet the diagnostic criteria for AMI in accordance with the Fourth Edition General Definition of Myocardial Infarction; 4. The patient or their legal representative signs an informed consent form.
Exclusion criteria
* 1\. Newly diagnosed acute myocardial infarction, angina pectoris, stroke or transient ischemic attack within the past 3 months; 2. Serious life-threatening diseases (such as advanced malignant tumors, end-stage kidney disease/liver disease, severe infections) with an estimated lifespan of less than 1 year; 3. Severe cognitive impairment, mental illness, inability to cooperate in completing follow-up, aging assessment, and related examinations; 4. Unable to complete assessment items such as grip strength, walking speed, and 6-minute walk test due to non cardiac reasons such as physical disabilities and severe bone and joint diseases; 5. Failed to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular events (MACE) | Baseline through 24 months of follow-up | The occurrence of major adverse cardiovascular events, including all-cause death, cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, stent restenosis or thrombosis, severe bleeding, and aging-related serious adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | Baseline through 24 months | Death from any cause during follow-up. |
| Cardiovascular mortality | Baseline through 24 months | Death attributable to cardiovascular causes, including sudden cardiac death, heart failure, or cardiogenic shock. |
| Hospitalization for heart failure | Baseline through 24 months | Hospital admission due to worsening heart failure requiring intravenous diuretics, inotropic agents, or vasoactive therapy. |
| Recurrent myocardial infarction | Baseline through 24 months | New acute myocardial infarction occurring during follow-up according to standard diagnostic criteria. |
| Aging-related serious adverse events | Baseline through 24 months | Aging-related adverse outcomes, including cognitive decline, frailty-related fracture after low-energy falls, or loss of activities of daily living. |
| Prognostic performance of the aging-related risk prediction model | At completion of the 24-month follow-up | Predictive performance of the prognostic model integrating clinical characteristics, aging assessments, and aging-related biomarkers, evaluated using discrimination and calibration metrics. |
Countries
China
Contacts
CONTACTMingwei W Wang, PhD
Outcome results
None listed